Luís Almeida

4.4k total citations
102 papers, 3.6k citations indexed

About

Luís Almeida is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Luís Almeida has authored 102 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Psychiatry and Mental health, 34 papers in Pediatrics, Perinatology and Child Health and 15 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Luís Almeida's work include Epilepsy research and treatment (38 papers), Pharmacological Effects and Toxicity Studies (25 papers) and Parkinson's Disease Mechanisms and Treatments (10 papers). Luís Almeida is often cited by papers focused on Epilepsy research and treatment (38 papers), Pharmacological Effects and Toxicity Studies (25 papers) and Parkinson's Disease Mechanisms and Treatments (10 papers). Luís Almeida collaborates with scholars based in Portugal, Germany and Brazil. Luís Almeida's co-authors include Patrício Soares‐da‐Silva, Amílcar Falcão, Teresa Nunes, Joana Maia, Manuel Vaz‐da‐Silva, Lyndon Wright, Christian E. Elger, Ana I. Loureiro, Amílcar Soares and Maria João Bonifácio and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

Luís Almeida

98 papers receiving 3.5k citations

Peers

Luís Almeida
Gail D. Anderson United States
James C. Cloyd United States
Larry Ereshefsky United States
L. F. Gram Denmark
John S. Markowitz United States
Bob Wilffert Netherlands
Carlos Perdomo United States
Cecilie Johannessen Landmark Norway
Svein I. Johannessen Norway
D J Greenblatt United States
Gail D. Anderson United States
Luís Almeida
Citations per year, relative to Luís Almeida Luís Almeida (= 1×) peers Gail D. Anderson

Countries citing papers authored by Luís Almeida

Since Specialization
Citations

This map shows the geographic impact of Luís Almeida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luís Almeida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luís Almeida more than expected).

Fields of papers citing papers by Luís Almeida

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luís Almeida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luís Almeida. The network helps show where Luís Almeida may publish in the future.

Co-authorship network of co-authors of Luís Almeida

This figure shows the co-authorship network connecting the top 25 collaborators of Luís Almeida. A scholar is included among the top collaborators of Luís Almeida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luís Almeida. Luís Almeida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Almeida, Luís, et al.. (2024). Elexacaftor/tezacaftor/ivacaftor, a game-changer in cystic fibrosis: The Portuguese experience. Pulmonary Pharmacology & Therapeutics. 87. 102328–102328. 2 indexed citations
3.
Albuquerque, João Porto de, et al.. (2023). Alternative Analysis Approaches for the Assessment of Pilot Bioavailability/Bioequivalence Studies. Pharmaceutics. 15(5). 1430–1430. 3 indexed citations
4.
5.
Cruz, Vítor Tedim, et al.. (2022). Sociodemographic and psychological characteristics influencing patients’ willingness to participate in clinical trials. BMJ Open Quality. 11(4). e002044–e002044. 16 indexed citations
6.
Twiss, James, et al.. (2016). Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire. Health and Quality of Life Outcomes. 14(1). 110–110. 8 indexed citations
7.
Oliveira, José Miguel P. Ferreira de, Maria Eugénia Marques Da Costa, Pedro Viana Pinto, et al.. (2014). Sulforaphane Induces Oxidative Stress and Death by p53-Independent Mechanism: Implication of Impaired Glutathione Recycling. PLoS ONE. 9(3). e92980–e92980. 48 indexed citations
8.
Almeida, Luís, Teresa Nunes, Raquel Costa, et al.. (2013). Etamicastat, a Novel Dopamine β-Hydroxylase Inhibitor: Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Hypertension. Clinical Therapeutics. 35(12). 1983–1996. 27 indexed citations
9.
Hufnagel, A., Elinor Ben‐Menachem, Alberto Alain Gabbai, et al.. (2012). Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: Results of a 1-year open-label extension study. Epilepsy Research. 103(2-3). 262–269. 68 indexed citations
10.
Nunes, Teresa, José Rocha, Amílcar Falcão, Luís Almeida, & Patrício Soares‐da‐Silva. (2012). Steady‐state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers. Epilepsia. 54(1). 108–116. 66 indexed citations
11.
Vaz‐da‐Silva, Manuel, Teresa Nunes, José Rocha, et al.. (2011). Effect of Food on the Pharmacokinetic Profile of Etamicastat (BIA 5-453). Drugs in R&D. 11(2). 127–136. 5 indexed citations
12.
Ferreira, Joaquim J., Olivier Rascol, Werner Poewe, et al.. (2010). A Double‐Blind, Randomized, Placebo and Active‐Controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease. CNS Neuroscience & Therapeutics. 16(6). 337–347. 18 indexed citations
13.
Nunes, Teresa, José Rocha, Manuel Vaz‐da‐Silva, et al.. (2010). Safety, Tolerability, and Pharmacokinetics of Etamicastat, a Novel Dopamine-β-Hydroxylase Inhibitor, in a Rising Multiple-Dose Study in Young Healthy Subjects. Drugs in R&D. 10(4). 225–242. 21 indexed citations
14.
15.
Vaz‐da‐Silva, Manuel, Ana I. Loureiro, Teresa Nunes, et al.. (2008). Pharmacokinetic-Pharmacodynamic Interaction between Nebicapone, a Novel Catechol-O-Methyltransferase Inhibitor, and Controlled-Release Levodopa/Carbidopa 200 mg/50 mg. Drugs in R&D. 9(6). 435–446. 4 indexed citations
16.
Ribeiro, Carlos, Tice Macedo, Teresa Nunes, et al.. (2008). Dosage Form Proportionality and Food Effect of the Final Tablet Formulation of Eslicarbazepine Acetate. Drugs in R&D. 9(6). 447–454. 16 indexed citations
17.
Elger, Christian E., Meir Bialer, Joyce A. Cramer, et al.. (2007). Eslicarbazepine Acetate: A Double‐blind, Add‐on, Placebo‐controlled Exploratory Trial in Adult Patients with Partial‐onset Seizures. Epilepsia. 48(3). 497–504. 110 indexed citations
18.
Almeida, Luís, et al.. (2005). Single‐Dose and Steady‐State Pharmacokinetics of Eslicarbazepine Acetate (BIA 2–093) in Healthy Elderly and Young Subjects. The Journal of Clinical Pharmacology. 45(9). 1062–1066. 88 indexed citations
19.
Ribeiro, Carlos, Teresa Nunes, Susana M. Tavares, et al.. (2005). Eslicarbazepine Acetate (BIA 2-093). Drugs in R&D. 6(5). 253–260. 18 indexed citations
20.
Almeida, Luís, Manuel Vaz‐da‐Silva, Amílcar Falcão, et al.. (2004). Pharmacokinetic–Pharmacodynamic Interaction Between BIA 3-202, a Novel COMT Inhibitor, and Levodopa/Carbidopa. Clinical Neuropharmacology. 27(1). 17–24. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gail D. Anderson Breakdown of academic impact, for papers by James C. Cloyd Breakdown of academic impact, for papers by Larry Ereshefsky Breakdown of academic impact, for papers by L. F. Gram Breakdown of academic impact, for papers by John S. Markowitz Breakdown of academic impact, for papers by Bob Wilffert Breakdown of academic impact, for papers by Carlos Perdomo Breakdown of academic impact, for papers by Cecilie Johannessen Landmark Breakdown of academic impact, for papers by Svein I. Johannessen Breakdown of academic impact, for papers by D J Greenblatt
Rankless by CCL
2026